Lineage Cell Therapeutics to Host Therapeutic Area Experts at Solebury Trout Investor Event on November 15, 2019
CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #AMD—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will participate in Solebury Trout’s KOL Event for analysts and investors on November 15, 2019 at 11am ET in New York City at the offices of White & Case, LLP. Lineage will begin with a corporate overview from Brian M. Culley, Chief Executive Officer and Edward D. Wirth, III, MD, PhD, Chief Medical Officer, which will be followed by presentations from Lineage therapeutic area experts Allen C. Ho, MD, FACS, Wills Eye Hospital Attending Surgeon and Director of Retina Research and John Steeves, BSc, PhD, Emeritus Principal Investigator, ICORD and Professor, Department of Neuroscience at the University of British Columbia.
Interested parties can access a live webcast of the Lineage presentations on the Events and Presentations section of Lineage’s website and an archived presentation will be available for 30 days.
Lineage Therapeutic Area Experts
OpRegen® Clinical Program
Allen C. Ho, M.D. FACS, Wills Eye Hospital Attending Surgeon and Director of Retina Research, Professor of Ophthalmology, Thomas Jefferson University
Dr. Ho maintains special interests in macular diseases, diabetic retinopathy, surgical retinal diseases and clinical trials investigating new treatments for vitreoretinal diseases including gene and cell therapies and new surgical drug delivery devices and techniques. His experience includes collaborative translational and clinical trial clinical research with expertise in study design, methodological testing, data analyses, surgical instrumentation and procedure development, execution and communication of these studies and their study results. He is the current President of The Retina Society and serves on its Executive Committee.
He has been Study Chair, Steering Committee Member or Principal Investigator of over 50 clinical trials. Dr. Ho has served on the US FDA Ophthalmic Device Panel, American Academy of Ophthalmology (AAO) Ophthalmic Retina Technology Assessment Committee, AAO Retina Measures Group, AAO IRIS Registry Committee and is past Chair of the AAO Retina Subspecialty Days and Vail Vitrectomy meetings. Through the Wills Eye Hospital Retina Fellowship he has mentored over 60 retina fellows and international research trainees. Dr. Ho has authored over 200 peer reviewed publications and several textbooks and is Editor-in-Chief of Current Opinion in Ophthalmology and Chief Medical Editor of Retina Today.
OPC1 Clinical Program
John Steeves, B.Sc., Ph.D., Emeritus Principal Investigator, ICORD, Professor, Department of Neuroscience, University of British Columbia
Dr. Steeves is currently a Professor in the Department of Neuroscience at the University of British Columbia and a Principal Investigator and Founding Director of ICORD (International Collaboration On Repair Discoveries), an interdisciplinary research centre focused on spinal cord injury. He also serves as the Chair of SCOPE (Spinal Cord Outcomes Partnership Endeavor), which works on translating discoveries to clinical trials. He obtained his B.Sc. and Ph.D. at the University of Manitoba and completed his Post-Doctoral Fellowship at the University of Alberta.
After a long career in basic science research, Dr. Steeves has turned his attention to translational research, making application of research to patients a higher priority. His current research focuses on arm and hand rehabilitation after spinal cord injuries. His goal is to improve rehabilitation strategies by using assistive robots and virtual-reality training. With a number of colleagues from across the globe, Dr. Steeves also works on developing better criteria for enrolling participants in SCI clinical trials, and on improving outcome measures of the electrical properties of the body and the nervous system. Better measurements of the outcomes of clinical trials can establish how well they help people with SCI, and therefore promote better recovery.
Dr. Steeves also collaborates with EMSCI (European Multicenter Study about Spinal Cord Injury) to analyze the database on SCI patients and their injuries to determine better clinical trial protocols.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia®, a facial aesthetics product that was recently granted a Conformité Européenne (CE) Mark. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
Solebury Trout IR
Gitanjali Jain Ogawa